Clinical Trials Directory

LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol)

THE STUDY WILL ANSWER WHETHER INHALED BUDESONIDE AND FORMOTEROL ARE ABLE TO ALLEVIATE OR PREVENT PULMONARY INJURY WHEN ADMINISTERED EARLY IN HOSPITAL COURSE TO THE PATIENTS AT RISK FOR DEVELOPING ARDS

Stanford is now accepting new patients for this trial.

Investigator(s):

Intervention(s):

  • drug : Placebo
  • drug : Budesonide and formoterol

Phase: Phase 2

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Adult patients (age > 18); - Admitted to the hospital through the emergency department (ED); - High risk of developing ARDS (Lung Injury Prediction Score-LIPS greater than or equal to four;

External Links

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Rosemary Vojnik
Recruiting

Footer Links: